EXAS
Price
$53.36
Change
-$0.50 (-0.93%)
Updated
Jul 3 closing price
Capitalization
12.78B
32 days until earnings call
XRAY
Price
$16.67
Change
+$0.10 (+0.60%)
Updated
Jul 3 closing price
Capitalization
6.69B
27 days until earnings call
Interact to see
Advertisement

EXAS vs XRAY

Header iconEXAS vs XRAY Comparison
Open Charts EXAS vs XRAYBanner chart's image
Exact Sciences
Price$53.36
Change-$0.50 (-0.93%)
Volume$1.67M
Capitalization12.78B
DENTSPLY SIRONA
Price$16.67
Change+$0.10 (+0.60%)
Volume$1.62M
Capitalization6.69B
EXAS vs XRAY Comparison Chart in %
Loading...
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XRAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXAS vs. XRAY commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXAS is a Hold and XRAY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (EXAS: $53.36 vs. XRAY: $16.67)
Brand notoriety: EXAS: Notable vs. XRAY: Not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: EXAS: 53% vs. XRAY: 59%
Market capitalization -- EXAS: $12.78B vs. XRAY: $6.69B
EXAS [@Medical Specialties] is valued at $12.78B. XRAY’s [@Medical Specialties] market capitalization is $6.69B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXAS’s FA Score shows that 0 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).

  • EXAS’s FA Score: 0 green, 5 red.
  • XRAY’s FA Score: 1 green, 4 red.
According to our system of comparison, both EXAS and XRAY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXAS’s TA Score shows that 4 TA indicator(s) are bullish while XRAY’s TA Score has 3 bullish TA indicator(s).

  • EXAS’s TA Score: 4 bullish, 5 bearish.
  • XRAY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, EXAS is a better buy in the short-term than XRAY.

Price Growth

EXAS (@Medical Specialties) experienced а +2.99% price change this week, while XRAY (@Medical Specialties) price change was +5.24% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.95%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was -0.02%.

Reported Earning Dates

EXAS is expected to report earnings on Aug 05, 2025.

XRAY is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Medical Specialties (+1.95% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXAS($12.8B) has a higher market cap than XRAY($6.69B). EXAS YTD gains are higher at: -5.036 vs. XRAY (-10.367). XRAY has higher annual earnings (EBITDA): 249M vs. EXAS (29.3M). EXAS has more cash in the bank: 778M vs. XRAY (334M). XRAY has less debt than EXAS: XRAY (2.3B) vs EXAS (2.56B). XRAY has higher revenues than EXAS: XRAY (3.97B) vs EXAS (2.5B).
EXASXRAYEXAS / XRAY
Capitalization12.8B6.69B191%
EBITDA29.3M249M12%
Gain YTD-5.036-10.36749%
P/E RatioN/A19.23-
Revenue2.5B3.97B63%
Total Cash778M334M233%
Total Debt2.56B2.3B111%
FUNDAMENTALS RATINGS
EXAS vs XRAY: Fundamental Ratings
EXAS
XRAY
OUTLOOK RATING
1..100
5721
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
5155
P/E GROWTH RATING
1..100
10090
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (4) in the Medical Specialties industry is somewhat better than the same rating for EXAS (42) in the Biotechnology industry. This means that XRAY’s stock grew somewhat faster than EXAS’s over the last 12 months.

XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as EXAS (100) in the Biotechnology industry. This means that XRAY’s stock grew similarly to EXAS’s over the last 12 months.

XRAY's SMR Rating (97) in the Medical Specialties industry is in the same range as EXAS (97) in the Biotechnology industry. This means that XRAY’s stock grew similarly to EXAS’s over the last 12 months.

EXAS's Price Growth Rating (51) in the Biotechnology industry is in the same range as XRAY (55) in the Medical Specialties industry. This means that EXAS’s stock grew similarly to XRAY’s over the last 12 months.

XRAY's P/E Growth Rating (90) in the Medical Specialties industry is in the same range as EXAS (100) in the Biotechnology industry. This means that XRAY’s stock grew similarly to EXAS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXASXRAY
RSI
ODDS (%)
Bearish Trend 5 days ago
70%
Bearish Trend 2 days ago
63%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
71%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
55%
MACD
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 2 days ago
63%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
61%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
58%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 22 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XRAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ACES27.580.99
+3.72%
ALPS Clean Energy ETF
CPZ16.390.02
+0.12%
Calamos Long/Short Equity & Dynamic Income Trust
FALN27.080.02
+0.07%
iShares Fallen Angels USD Bond ETF
NEWTZ24.91N/A
N/A
NewtekOne
MBNE28.62N/A
N/A
SPDR® Nuveen Municipal Bond ESG ETF

EXAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with ILMN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then ILMN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAS
1D Price
Change %
EXAS100%
-0.93%
ILMN - EXAS
36%
Loosely correlated
+0.46%
CDNA - EXAS
34%
Loosely correlated
-1.28%
A - EXAS
33%
Loosely correlated
+0.60%
XRAY - EXAS
33%
Poorly correlated
+0.60%
BRKR - EXAS
32%
Poorly correlated
-0.02%
More

XRAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRAY
1D Price
Change %
XRAY100%
+0.60%
NVST - XRAY
54%
Loosely correlated
+1.09%
QDEL - XRAY
49%
Loosely correlated
+0.03%
STE - XRAY
47%
Loosely correlated
-0.29%
KIDS - XRAY
46%
Loosely correlated
+1.54%
AZTA - XRAY
45%
Loosely correlated
+1.16%
More